From the National Health Council (NHC) and National Organization for Rare Disorders (NORD):
People with chronic and rare diseases and disabilities rely on FDA to access innovative, safe, and effective treatments. Not only do user fees provide the funding for FDA to quickly review products, but the current user fee agreements also provide significant improvements and advancements to the health care community that simply cannot wait.
For more information about the letter and to sign using our online form, please click here. We ask that all signatures be submitted by April 20.